VNRX Stock Summary and Trading Ideas (Volitionrx | AMEX:VNRX)

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Volitionrx trades on the AMEX stock market under the symbol VNRX.

As of September 1, 2026, VNRX stock price declined to $0.38 with 1,380,999 million shares trading.

VNRX has a beta of 2.78, meaning it tends to be more sensitive to market movements. VNRX has a correlation of 0.10 to the broad based SPY ETF.

VNRX has a market cap of $5.40 million. This is considered a Sub-Micro Cap stock.

Last quarter Volitionrx reported $398,657 in Revenue and -$.85 earnings per share. This fell short of revenue expectation by $-90,815 and missed earnings estimates by -$.17.

In the last 3 years, VNRX traded as high as $27.60 and as low as $.33.

The top ETF exchange traded funds that VNRX belongs to (by Net Assets): VXF.

VNRX has underperformed the market in the last year with a price return of -97.2% while the SPY ETF gained +19.3%. VNRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -85.8% and -24.0%, respectively, while the SPY returned +1.0% and -1.4%, respectively.

VNRX support price is $.39 and resistance is $.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNRX shares will trade within this expected range on the day.